Aspirin and Cancer

Paola Patrignani, Carlo Patrono

Risultato della ricerca: Contributo in rivistaArticolo in rivista

137 Citazioni (Scopus)


The place of aspirin in primary prevention remains controversial, with North American and European organizations issuing contradictory treatment guidelines. More recently, the U.S. Preventive Services Task Force recommended “initiating low-dose aspirin use for the primary prevention of cardiovascular disease (CVD) and colorectal cancer in adults aged 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years.” This recommendation reflects increasing evidence for a chemopreventive effect of low-dose aspirin against colorectal (and other) cancer. The intent of this paper is to review the evidence supporting a chemopreventive effect of aspirin, discuss its potential mechanism(s) of action, and provide a conceptual framework for assessing current guidelines in the light of ongoing studies.
Lingua originaleEnglish
pagine (da-a)967-976
Numero di pagine10
RivistaJournal of the American College of Cardiology
Stato di pubblicazionePubblicato - 2016
Pubblicato esternamente


  • Aspirin
  • Cardiology and Cardiovascular Medicine
  • Cardiovascular Diseases
  • Colorectal Neoplasms
  • Dose-Response Relationship, Drug
  • Humans
  • Platelet Aggregation Inhibitors
  • Practice Guidelines as Topic
  • Primary Prevention
  • chemoprevention
  • colorectal neoplasms
  • cyclooxygenase-1
  • nonsteroidal anti-inflammatory agents
  • platelet activation
  • prostaglandins


Entra nei temi di ricerca di 'Aspirin and Cancer'. Insieme formano una fingerprint unica.

Cita questo